The Justice Department has announced the indictment of two Indian nationals involved in a scheme to smuggle counterfeit Ozempic, a diabetes medication, into the United States. This operation not only violates U.S. drug laws but also poses significant health risks to consumers.
According to the indictment, the defendants were responsible for importing large quantities of the counterfeit drug, which was marketed as authentic Ozempic. The counterfeit versions may contain harmful substances, endangering the health of those who unknowingly consume them.
The Justice Department is urging the public to remain vigilant and only purchase medications from licensed pharmacies. This case highlights the ongoing battle against counterfeit drugs and the importance of ensuring medication safety for consumers.